Primary antiphospholipid syndrome and antiphospholipid syndrome associated to systemic lupus: Are they different entities?

Cristina Belizna*, Ljudmila Stojanovich, Jan Willem Cohen-Tervaert, Celine Fassot, Daniel Henrion, Laurent Loufrani, Gyorgy Nagy, Christian Muchardt, Milena Hasan, Marie Noelle Ungeheuer, Laurent Arnaud, Jaume Alijotas-Reig, Enrique Esteve-Valverde, Ferdinando Nicoletti, Patrick Saulnier, Alban Godon, Pascal Reynier, Jean Marie Chretien, Laura Damian, Loukman OmarjeeGuillaume Mahe, Marc Antoine Pistorius, Pier Luigi Meroni, Katrien Devreese

*Corresponding author for this work

Research output: Contribution to journal(Systematic) Review article peer-review

16 Citations (Web of Science)

Abstract

Primary antiphospholipid syndrome (PAPS) and antiphospholipid syndrome associated to lupus (SAPS) have several overlapping characteristics. As systemic manifestations are also reported in patients with PAPS, and as a subgroup of PAPS patients could evaluate to a SAPS, the differentiation between the two types of APS could be performed based on the clinical experience of the medical teams and is related to a variety of clinical, biological, histological and genetic features. Several data are available in the literature with respect to the identification of distinctive features between these two entities. However, there are some limitation in the interpretation of results issued from studies performed prior to updated Sydney criteria. Based on recent data, a certain number of features more frequent in one type of APS as compared to the other could be distinguished. The major differentiation between these two entities is genetical. New genetic data allowing the identification of specific subgroups of APS are ongoing.
Original languageEnglish
Pages (from-to)739-745
Number of pages7
JournalAutoimmunity Reviews
Volume17
Issue number8
DOIs
Publication statusPublished - 1 Aug 2018

Keywords

  • Antiphospholipid syndrome
  • Primary antiphospholipid syndrome
  • Secondary antiphospholipid syndrome
  • ANTIBODY TYPE
  • SYNDROME APS
  • ANNEXIN A5
  • CLASSIFICATION CRITERIA
  • CARDIAC MANIFESTATIONS
  • THROMBOGENIC MECHANISM
  • CARDIOVASCULAR-DISEASE
  • ANTICOAGULANT ACTIVITY
  • ERYTHEMATOSUS
  • SECONDARY

Cite this